Perioperative Pembrolizumab in Resectable HNSCC: Ten-Year Evidence Review
This narrative review places the single positive phase III perioperative trial (KEYNOTE-689) against a decade of negative chemoradiotherapy-immunotherapy trials and defines what oncology pharmacists can and cannot act on today.
📅 Journal publication: 2026(online Oct 19, 2026)·Last updated: Nov 8, 2026
Pembrolizumab shows promise in perioperative treatment of resectable HNSCC.
Perioperative immune checkpoint inhibitors may improve outcomes in head and neck squamous cell carcinoma (HNSCC). The KEYNOTE-689 trial showed improved event-free survival with perioperative pembrolizumab in HNSCC patients with PD-L1 combined positive score (CPS) ≥1. While pembrolizumab is beneficial in specific HNSCC patients, optimal perioperative regimens and guidelines are still emerging. Pembrolizumab in perioperative settings shows promise for certain HNSCC patients, backed by KEYNOTE-689.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Freeman H, Rawson C, Al-Saidi N, Lucke-Wold B, Karsy M, Pahlevani M
Citation:Freeman H, Rawson C, Al-Saidi N, et al. Perioperative immune checkpoint inhibition in head and neck squamous cell carcinoma: a 10-year review. Exploration of targeted anti-tumor therapy. 2026;7:1002406. doi:10.37349/etat.2026.1002406